AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03010670 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
Study NCT01074372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN727
Description: 4 cohorts (dose 1, 2, 3, 4)
Study NCT01135953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct Stimulation (tDCS) and D-cycloserine
Description: Transcranial Direct Stimulation applied to the motor cortex every day of the week (5 sessions) at 2mA, during 20 minutes. Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).~D-cycloserine, administered orally (capsules), 100 mg, twice a week (Monday and Thursday), prior to the tDCS session.
Study NCT01074372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 cohorts (dose 1, 2, 3, 4)
Study NCT04693117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Training
Description: All individual of interventional group participated in an interval training program, which comprised of 3 days/week for twelve weeks. A booklet was given to each participant containing instructions and guideline about interval training. The interval training program was introduced as prescribed previously.17 After the workout, a cool down period of 5 minutes was given during which they perform paddling with low speed. All training program was supervised by a qualified physical therapist.
Study NCT00907712 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: cardiac echo examination
Description: cardiac echo examination - before and after the surgery
Study NCT02730689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R207
Study NCT02730689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DP-R207
Study NCT02730689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT02730689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Study NCT02730689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Study NCT02730689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Study NCT01761175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided infraclavicular block
Description: Ultrasound-guided single injection infraclavicular block: using an in-plane technique, 30 mL of mepivacaine 1.5% is injected at the posterior aspect of the artery.
Study NCT01761175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided axillary block
Description: Ultrasound-guided double injection axillary block: using an in-plane technique, 25 mL of mepivacaine 1.5% is injected postero-medial to the artery. During needle withdrawal, 5 mL of the same solution is injected close to the musculocutaneous nerve.
Study NCT01825070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Montmorency cherry concentrate
Description: Tart Montmorency cherry juice concentrate
Study NCT05501223 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medication review
Description: 30-60 minutes extra consultation regarding the patients drugs
Study NCT05501223 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Standard care i.e. visit at the Dept. of Endocrinology.
Study NCT02640573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the AdultsQLTM 3.0 Sickle Cell Disease Module after 6 months at MTD, compared to entrance scores
Study NCT00784641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel Bausch & Lomb daily disposable contact lenses
Description: Lenses to be worn and replaced daily for 2 weeks.
Study NCT00784641 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bausch & Lomb SofLens daily disposable contact lenses.
Description: Lenses to be worn and replaced daily for 2 weeks.
Study NCT00784641 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Johnson and Johnson 1-Day Acuvue Moist contact lenses
Description: Lenses to be worn and replaced daily for 2 weeks.
Study NCT03211871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intraoperative intravenous dexmedetomidine infusion 0,5 mcg/kg/h
Study NCT03211871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution_#1
Description: Intraoperative intravenous normal saline infusion
Study NCT00622973 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Imaging: diffusion-weighted MRI
Description: Diffusion-weighted MRI of the entire pelvis to detect lymph node metastases
Study NCT00622973 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sinerem (USPIO) enhanced MRI
Description: USPIO (Sinerem) will be administered intravenously immediately after the first MR examination at a dose of 2.6 mg Fe/kg body weight diluted in 100 ml of saline (optimal dose according to: (9, 10)) during a period of about 30 minutes under medical supervision. Postcontrast MR imaging will be performed 24-36 hours after contrast medium injection.
Study NCT02796690 — intervention group
Intervention type: OTHER
Intervention: nasal swabs will be collected
Description: After formal consent, nasal swabs are collected for each participant. SA nasal carriage and its susceptibility to methicillin is determined using a rapid PCR technique (GenExpert, Cepheid). Each participant is asked to complete a short questionnaire regarding some demographic variables, smoking habits, long-term medication, sector of activity, and direct manipulation of the pathogen.
Study NCT02345226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/RPV/TAF
Description: 200/25/25 mg FDC tablets administered orally once daily
Study NCT01850849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 39652 cream
Study NCT01850849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cream vehicle
Study NCT02846376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a fully humanized immunoglobulin 4 (IgG4) monoclonal antibody (mAb) which binds to PD-1 (CD279) with nanomolar affinity and shows a high degree of specificity for PD-1; blocking binding of PD-1 to PD-L1 and PD-L2. Nivolumab binds selectively to human PD-1 and does not bind to other members of the cluster of differentiation protein 28 (CD28) family.
Study NCT02846376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a recombinant, human mAb that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab is an immunoglobulin 1 (IgG1) kappa immunoglobulin with an approximate molecular weight of 148 kilo-Daltons (kDa). Ipilimumab is produced in mammalian (Chinese hamster ovary) cell culture.
Study NCT00096746 — intervention group
Intervention type: DRUG
Intervention: LPV/RTV + 2NRTIs
Description: Tablets, Oral, Variable, Twice daily, 48 weeks.
Study NCT03156556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mood Mechanic Course
Description: French-Canadian version of the Mood Mechanic Course. Performed by a professional translator (Bourret Translation Inc.) and reviewed by the research supervisor, Professor France Talbot, clinical psychologist as well with expertise in CBT.
Study NCT02372292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous furosemide
Description: Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion
Study NCT02883465 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Diaphragmatic ultrasound
Description: All patients will have a diaphragmatic ultrasound in the 4 hours before the extubation.~* a record of the right and left diaphragmatic cupolas run, with a chest approach and using a 4-5 MHz (megahertz) cardiac or abdominal sensor. 3 acquisitions for each side~* a record of the diaphragm thickening at the right and left apposition zones with a 10-12 MHz (megahertz) vascular sensor. 3 acquisitions for each side
Study NCT03774693 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia with fentanyl boluses
Description: Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1
Study NCT01577407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: Subjects will be infused intravenously with nefopam (20mg/2mL) over a course of 30 minutes in a supine position. There will be a single administration of IV 20 mg nefopam and IV placebo. Each intervention will occur on a separate day.
Study NCT01577407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nefopam
Description: Subjects will be infused intravenously with nefopam (20mg/2mL) over a course of 30 minutes in a supine position. There will be a single administration of IV 20 mg nefopam and IV placebo. Each intervention will occur on a separate day.
Study NCT03399006 — intervention group
Intervention type: DEVICE
Intervention: 2D ultrasound
Description: Trans-abdominal ultrasound examination was performed with the woman placed in a recumbent or semi recumbent position \& carried out for measurement of fetal CRL and diagnosis of any major fetal defects
Study NCT03399006 — intervention group
Intervention type: DEVICE
Intervention: Doppler Ultrasound
Description: measurement of UtA-PI \& UtA-RI. A sagittal section of the uterus was obtained For the Doppler studies, and the cervical canal and internal cervical os were identified. The transducer was gently tilted from side to side and color flow mapping was used to identify each UtA along the side of the cervix and uterus at the level of the internal os.~When three similar consecutive waveforms had been obtained the UtA-PI and UtA-RI were measured, and the mean UtA-PI and UtA-RI of the left and right arteries were calculated.
Study NCT03399006 — intervention group
Intervention type: DEVICE
Intervention: 3D ultrasound
Description: 3D transabdominal ultrasound of the Placental volume: the transducer with a full bladder and the transducer placed perpendicular to the placenta to see the entire placenta. The adjustments to 3D placental scan were an angle of 70° and a maximum region of interest that allowed the full placental surface. The external limits of the placenta were defined by the basal plate and the chorionic plate excluding the myometrium. Another acquisition was done, if the quality criteria were not attained.~After sonography, the placental volume was calculated with 4D View software (GE Healthcare) by a single operator. The calculation was done twice using the same image, and the time spent was recorded. The VOCAL mode with an angle of rotation of 30° was chosen; the axial plane was the reference; and the calipers were placed on either side of the placenta. With 6 planes, it was possible to reconstruct the volume measured in cubic centimeters.
Study NCT03774693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional block
Description: Patients will receive trans-oral bilateral sphenopalatine ganglion block and trans-oral bilateral infraorbital nerve block.
Study NCT04755296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: Low level laser therapy was applied immediately before each aerobic exercise training session by using a multidiode cluster (with four diode spots; Polaris2, manufactured by Astar ABR, Poland) )on 12 sites on the lower limb (6 on quadriceps ( 2 centrally on rectus femoris and vastus intermedius,2 laterally on vastus lateralis, and two medially on vastus medialis), 4 on hamstrings and 2 on gastrocnemius) with the following parameters: 808 nm, continous output, 200 mW each diode (total of 800 mW) power output, 24 J energy on each site (6 J for each spot) , 40 seconds at each site (8 minutes of total treatment time in lower limb) and 288 J total energy delivered per lower limb, 48 irradiation points per lower limb ,3 sessions weekly for 12 weeks.
Study NCT04755296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercises
Description: Aerobic exercise program consisted of walking on the treadmill at a rate of 3 sessions/week for 12 weeks, with each session lasting for 40 minutes in the form of warming up for 5 minutes at intensity of \<50% of the previously determined VO2max of each participant, 30 minutes of treadmill exercises at intensity of (70-85%) of the previously determined VO2max of each participant then 5 minutes cooling down at intensity of\<50% of the previously determined VO2max of each participant.
Study NCT04755296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercises
Description: Aerobic exercise program consisted of walking on the treadmill at a rate of 3 sessions/week for 12 weeks, with each session lasting for 40 minutes in the form of warming up for 5 minutes at intensity of \<50% of the previously determined VO2max of each participant, 30 minutes of treadmill exercises at intensity of (70-85%) of the previously determined VO2max of each participant then 5 minutes cooling down at intensity of\<50% of the previously determined VO2max of each participant.
Study NCT04755296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy program
Description: Patients were received traditional physical therapy program in the form of (stretching and strengthening exercises for all affected areas, diaphragmatic breathing exercises and activities of daily living).
Study NCT04755296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy program
Description: Patients were received traditional physical therapy program in the form of (stretching and strengthening exercises for all affected areas, diaphragmatic breathing exercises and activities of daily living).
Study NCT03356158 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPGJ602
Description: Injection, q.w., 20 mg: 100 ml
Study NCT02010294 — intervention group
Intervention type: GENETIC
Intervention: DNA samples, GAS strains
Description: DNA samples,GAS strains
Study NCT01273857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous cardiac progenitor cell transplantation
Description: Patients will receive 0.3 million / kg of autologous cardiac progenitor cells via intracoronary delivery 1 month after cardiac surgery. Follow-up visits 3 months to 1 year after cell injection will need to prospectively verify the clinical, laboratory, and safety-related data.
Study NCT01273857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: staged shunt procedure
Description: Norwood-Glenn, Glenn, or Fontan procedure will be applied
Study NCT01273857 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: staged shunt procedure
Description: Norwood-Glenn, Glenn, or Fontan procedure will be applied
Study NCT02219308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paracervical Block (PCB)
Description: Drug: 1% Lidocaine Hydrochloride~Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix and 18 mL 1% buffered lidocaine solution evenly distributed between 4 o'clock and 8 o'clock positions of cervix with standard 22 gauge spinal needle.~IUD placement then proceeds
Study NCT02219308 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No Paracervical Block (Sham PCB)
Description: Drug: 1% Lidocaine Hydrochloride~Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix with standard 22 gauge spinal needle. Capped spinal needle is then held against the cervix at 4 o'clock and 8 o'clock positions of cervix, lightly so as not to cause blanching, indentation, or pain.~IUD placement then proceeds
Study NCT03992313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based HCV rapid test
Description: HCV rapid tests will be done in the village
Study NCT02345226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV/FTC/TDF Placebo
Description: Tablets administered orally once daily
Study NCT01201044 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine, Nedaplatin, iV
Description: Gemcitabine, Injection, 1000mg/m2, D1 \& D7/ 4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles.
Study NCT01201044 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 3DCRT
Description: non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.
Study NCT01201044 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3DCRT
Description: non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.
Study NCT01201044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine，Nedaplatin, BAI
Description: Drug: Gemcitabine, Nedaplatin, iV~Gemcitabine, Injection, 1000mg/m2, D1/4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles. BAI
Study NCT02345226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV/FTC/TDF
Description: 600/200/300 mg FDC tablets administered orally once daily
Study NCT02416544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lunch which is calorie-restricted and low-salt
Description: Comparison of different duration of feeding lunch which is calorie-restricted and low-salt
Study NCT02367885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-850 0.5 mL injection
Description: TAK-850 injection
Study NCT02345226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/RPV/TAF Placebo
Description: Tablets administered orally once daily
Study NCT01571310 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Omitted Breakfast
Description: Experimental:The patients in Omitted Breakfast day will omit the breakfast and will continue the overnight fast until lunch. They will eat only lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00
Study NCT01571310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omitted Breakfast
Description: Experimental:The patients in Omitted Breakfast day will omit the breakfast and will continue the overnight fast until lunch. They will eat only lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00
Study NCT01571310 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast
Description: In the Active Comparator: The patients in the Breakfast day will consume breakfast (700 kcal) at 8:00 , lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00~(YesB): The patients in YesB will eat all three mealswill consume three meals:
Study NCT01571310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast
Description: In the Active Comparator: The patients in the Breakfast day will consume breakfast (700 kcal) at 8:00 , lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00~(YesB): The patients in YesB will eat all three mealswill consume three meals:
Study NCT01844557 — intervention group
Intervention type: OTHER
Intervention: Swallowing Exercises
Description: Participants perform 3 swallowing exercises.
Study NCT01844557 — intervention group
Intervention type: BEHAVIORAL
Intervention: Symptom Inventory
Description: Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before swallowing exercise procedure.
Study NCT01844557 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants fill out 3 questionnaires after swallowing exercises. The questionnaires will take about 10 minutes to complete.
Study NCT01372228 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hematopoietic stem cell infusion
Description: Enriched hematopoetic stem cell infusion
Study NCT03815474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib
Description: Anlotinib 12 mg once daily for 14 days tablet by mouth ; epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day with 6 cycles. Anlotinib 12 mg once daily for 14 days tablet by mouth to progressive disease
Study NCT03086278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-008
Description: AST-008 is a toll-like receptor 9 agonist.
Study NCT02173938 — intervention group
Intervention type: OTHER
Intervention: Tobacco Dependence Treatment
Description: face to face, outpatient tobacco dependence treatment based on the Public Health Service guidelines for treating tobacco use and dependence
Study NCT02891109 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological tests
Description: From the blood: B and T cells extraction then co-culture B and T cells and characterization of lymphocytes by flow cytometry
Study NCT01706796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340
Description: Oral solution, single dose, fasted
Study NCT01706796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340
Description: Immediate Release Tablet, single dose, fasted
Study NCT01706796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340
Description: Modified Release Tablet (short duration, MR1), single dose, fasted
Study NCT01706796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340
Description: Modified Release Tablet (long duration, MR2), single dose, fasted
Study NCT01706796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340
Description: Modified Release Tablet (short duration, MR1), single dose, fed
Study NCT01706796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340
Description: Modified Release Tablet (long duration, MR2), single dose, fed
Study NCT04245072 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection
Description: Intravitreal injection of Aflibercept 2 mg (0.05 ml) or Ranibizumab 0.5 mg (0.05 ml) to the regimen pro re nata.